Candriam SCA’s Atara Biotherapeutics ATRA Stock Holding History

Candriam SCA’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,846	Closed	-$390K	–	731
2023 Q1	$390K	Sell	5,846 -1,796	-24%	-$174K	﹤0.01%	827
2022 Q4	$627K	Sell	7,642 -1,342	-15%	-$140K	﹤0.01%	779
2022 Q3	$849K	Buy	+8,984	New	+$1.01M	0.01%	743
2016 Q2	–	Sell	-2,220	Closed	-$1.05M	–	659
2016 Q1	$1.05M	Buy	+2,220	New	+$999K	0.03%	422
2015 Q4	–	Sell	-1,628	Closed	-$1.28M	–	580
2015 Q3	$1.28M	Buy	1,628 +1,028	+171%	+$1.25M	0.03%	407
2015 Q2	$791K	Buy	+600	New	+$688K	0.02%	477

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Candriam SCA's ATRA Position: Q2 2023 in Review

Candriam SCA sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 5,846 shares — an estimated $390K sold.

Candriam SCA first reported a position in ATRA in Q2 2015 and held it in 6 quarters. The position peaked at $1.28M in Q3 2015. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

Candriam SCA reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 5,846 Atara Biotherapeutics shares in Q2 2023, an estimated $390K.
Candriam SCA first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 6 quarters.
Candriam SCA's Atara Biotherapeutics position peaked at $1.28M in Q3 2015.
118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.